## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 2.36 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($123.83)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Price-Driven Insight from (ZTS) for Rule-Based Strategy**
- Source: Stock Traders Daily | 20260104T040400 | Somewhat-Bearish | Relevance: 100%
- This article provides a price-driven insight into Zoetis Inc. Class A (NYSE: ZTS) for rule-based trading strategies. It highlights a mixed sentiment alignment indicating choppiness, an exceptional short setup, and divergent sentiment across horizons. The report also details three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones for different risk profiles.

**2. IDEXX Laboratories: How a Quiet Diagnostics Giant Is Rewriting the Future of Animal Health**
- Source: AD HOC NEWS | 20260104T060839 | Somewhat-Bullish | Relevance: 72%
- IDEXX Laboratories has transformed veterinary diagnostics into a high-margin, high-tech platform business by integrating in-clinic analyzers, reference lab services, software, and AI tools. This ecosystem approach provides a unified workflow for veterinary practices and addresses the rising demand for sophisticated animal healthcare amidst workforce shortages. The company's unique selling proposition lies in its data and AI capabilities, workflow integration, and recurring revenue model, contributing to its strong market valuation and competitive edge against rivals like Zoetis and Antech Diagnostics.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 11.9% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.36 elevated, pricing in significant growth expectations. Forward P/E 19.1x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $57.3B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.36 |
| Forward P/E | 19.1 |
| Current P/E | 20.4 |
| YoY Growth | 7.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (1.02), confirming momentum. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.10% (CS: 62) | Neutral |
| RSI_14 | 63.8 | Neutral |
| MACD Histogram | 1.02 | Bullish |
| vs SMA20 | 1.051x | Above |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 0.881x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $129.37
- **Stop Loss:** $123.83 (4.3% risk)
- **Target:** $134.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 238
- **Position Value:** $30,790.06
- **Portfolio %:** 30.79%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*